Duration of diabetes may, therefore, partly explain the glycaemic findings reported in our study
Related PDB-101 Resources Browse Drug Action Browse You and Your Health Browse Diabetes Browse Biomolecular Structural Biology References 6LN2: Wu F, Yang L, Hang K, Laursen M, Wu L, Han GW, Ren Q, Roed NK, Lin G, Hanson MA, Jiang H, Wang MW, Reedtz-Runge S, Song G, Stevens RC
FeelGood's three-entity structure - platform, medical group, third-party pharmacy - is publicly documented
Quick Links GLP2 The Imbalanced Dual Incretin Agonist Also known as: LY3298176 Why Researchers Choose GLP2-T Unlike selective GLP-1 receptor agonists, GLP2 peptide is engineered with an imbalanced receptor binding profilematching native GIP affinity while binding GLP-1 receptors with approximately 5-fold weaker affinity